Stage-specific Case Management for Early Psychosis

November 10, 2020 updated by: Professor Eric Y.H. Chen, The University of Hong Kong

Outcome of Stage-specific Early Intervention for Psychosis in Hong Kong: A Randomized Controlled Study

One of the commonly adopted strategies in improving outcome in psychotic disorders is by focused, specific and intensive intervention in the initial few years of the disorder. However the effects of intervention and the optimal duration of intervention have seldom been examined in randomized studies. This study uses a randomized controlled study design to investigate the effectiveness of stage-specific case-management in improving outcome of first episode psychotic disorders. It also addresses whether two years of case-management is less effective than four years of case-management over a four year period. A total of 360 subjects, who aged 25 above, and diagnosed with first episode psychotic disorders, will be and randomized into 3 groups: (1) standard care alone without case management, (2) two-year case management, (3) four-year case management. All groups will receive usual standard care treatment. This four-year follow-up study will assess symptoms, functioning, quality of life as well as health economics data.

Study Overview

Status

Completed

Conditions

Detailed Description

Psychotic disorder is a debilitating illness which imposes substantial impact to the patients, their families, and the society. The provision of early intervention provides a window of opportunity to minimize the social and economic burden incurred by the illness.

Many previous studies of effectiveness of early intervention used the historical control approach and are subjected to cohort effects. For example, change of medication pattern over time could potentially lead to differences in outcome. In addition, few studies provide longer-term outcome data of treatment program beyond two years. The optimal length of intervention has not been determined, and many programmes used 12-24 month intervention mainly based on resources available. It is also important to ask whether favorable effects of early intervention could be sustained over time. Further analyses will be done to assess whether EI effects are more pronounced in particular subgroups including DUP, age, sex and diagnosis.

The proposed study aims to address these issues by using a randomized controlled design to investigate the longer-term (4 year) outcome of patients with first episode psychosis. The study randomizes 360 patients with first episode psychotic disorders into 3 groups: (1) standard care (outpatient based care with inpatient and community care as required); (2) standard care with 2 years of add-on stage specific case-management (individualized care delivered by designated case managers according to specific protocol); and (3) standard care with 4 years of add-on stage specific case management.

The study hypothesis are: (1) both 2 years and 4 years of case management produce better outcomes than standard care alone; (2) 4 years of case management produces better outcome than 2 years of case management.

Study Type

Interventional

Enrollment (Actual)

360

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, China
        • The University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

26 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis nos or delusional disorder
  • Cantonese-speaking Chinese
  • Ability to understand the nature of the study and sign informed consent
  • Capacity to participate in cognitive testing

Exclusion Criteria:

  • Organic Brain disorder
  • Known history of intellectual disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: case management (4 yrs)
4-year case management and standard care
Stage-specific case-management for psychosis by designated key-workers according to specified protocol
Active Comparator: case management (2 yrs) and standard care (2 yrs)
2-year case management and standard care
Stage-specific case-management for psychosis by designated key-workers according to specified protocol
No Intervention: standard care (4 yrs)
standard care for 4 years

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Functioning (social and occupational)
Time Frame: baseline, 6-month, 12-month, 24-month, 36-month, 48-month
baseline, 6-month, 12-month, 24-month, 36-month, 48-month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Psychotic symptoms
Time Frame: baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Psychotic symptoms will be assessed using the Positive and Negative Syndrome Scale (PANSS)
baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Psychotic symptoms
Time Frame: baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Psychotic symptoms will be assessed using Scale for the Assessment of Positive Symptoms (SAPS)
baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Psychotic symptoms
Time Frame: baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Psychotic symptoms will be assessed using Scale for the Assessment of Negative Symptoms (SANS).
baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Depressive symptoms
Time Frame: baseline, 12-month, 24-month, 36-month, 48-month
Depressive symptoms will be assessed using the Calgary Depression Scale for Schizophrenia (CDSS).
baseline, 12-month, 24-month, 36-month, 48-month
Neurocognitive functioning
Time Frame: baseline, 12-month, 24-month, 36-month, 48-month
A battery of neurocognitive tests will be conducted, including Handedness, Trail Making, Wisconsin Card Sorting Test, Semantic Verbal Fluency, Logical Verbal Memory, Visual Patterns Test, Letter Number Span, Monotone Counting, and Soft Neurological Signs.
baseline, 12-month, 24-month, 36-month, 48-month
Health economics
Time Frame: baseline, 6-month, 12-month, 24-month, 36-month, 48-month
baseline, 6-month, 12-month, 24-month, 36-month, 48-month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

June 10, 2009

First Submitted That Met QC Criteria

June 10, 2009

First Posted (Estimate)

June 12, 2009

Study Record Updates

Last Update Posted (Actual)

November 13, 2020

Last Update Submitted That Met QC Criteria

November 10, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • jcep-rct

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychotic Disorders

Clinical Trials on stage-specific case-management

3
Subscribe